☆
Watchlist
Log in
Sign-up
Inoviq Ltd (iiq) Logo

Inoviq Ltd (IIQ)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials (10-yr)

IIQ Chart

Snapshot

IIQ's Principal Activity is the research and development of non-invasive diagnostic tests for early detection of cancer.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -62.98%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,246 of 2,427
Sector Rank 100 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies OSL / CYP / NTI
EPS -$0.147
DPS $0.00
Book Value Per Share $0.36

Broker Consensus

IIQ is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Top Market Index News

More News

Announcements

Date Heading Pages File Size Time

Corporate Overview

INOVIQ Ltd (IIQ , formerly BARD1 Life Sciences Limited)is developing and commercialising an innovative portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.

Incorporation Details

Incorporated in WA as Esmeralda Exploration Pty Ltd on 30/06/1983. Name changed to Esmeralda Exploration Ltd on 08/10/1985. Industry classification changed from 012 to 011 Gold (Gold Producer) on 08/02/2002. Name changed to Eurogold Limited on 28/05/2002.

Corporate Details

Head Office Notting Hill VIC 3168
Website www.inoviq.com
Registry Computershare
Auditor Grant Thornton Audit Pty Ltd
Date Listed -

Upcoming Calendar (Forecasted)

Date Event
30/08/2022 Report (Prelim)
28/09/2022 Report (Annual)
19/10/2022 Report (Annual)
24/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Geoffrey A. Cumming Non-Executive Chairman,Non-Executive Director Jul 2020

Mr Geoffrey A. Cumming

Non-Executive Chairman,Non-Executive Director

Dr Cumming has held senior roles in the global healthcare and biotechnology sector for more than 20 years. As Managing Director, Roche Diagnostic Systems (Oceania), Dr Cumming transformed the loss-making entity the Swiss parent was intending to divest, into the fastest growing and most profitable affiliate in the Roche group. In his role as Managing Director/CEO of Biosceptre International Ltd, Dr Cumming was successful in designing and securing key funding arrangements through a skilful range of capital raising initiatives, including large government grants, partnering and co-development deals. His most recent executive role was as Managing Director / CEO of Anteo Diagnostics Ltd (ASX: ADO). He is currently a Nonexecutive Director of Anteo Diagnostics Ltd and was previously Chairman of Sienna Cancer Diagnostics Ltd and a Nonexecutive Director of Medical Australia Ltd (ASX: MLA). Dr Cumming is the Chair of the Remuneration Committee

Mr Tony Di Pietro Joint Company Secretary,Chief Financial Officer Jul 2020
Professor Allan Cripps Non-Executive Director Jan 2020

Professor Allan Cripps

Non-Executive Director

Prof Cripps is an academic, clinical scientist and health services leader, having made contributions in immunology, diagnostics, and health services delivery. From 2005 to 2016, Prof Cripps was the Pro Vice Chancellor (Health) at Griffith University and is currently a research Prof at Griffith University, leading the Mucosal Immunology Research Group within the Menzies Health Institute Queensland. Prof Cripps had near 20 years' experience in the health and pharmaceutical industries before becoming a full-time academic focusing his research on mucosal immunology, respiratory tract infections, vaccine development and diagnostics. He has published over 300 peer reviewed scientific papers, presented at numerous international scientific conferences, received over $17 million in Government and industry grant funding and is co-inventor on several international patents in the fields of diagnostics and vaccine protein antigens. He is a fellow of the Australian Academy of Health and Medical Scientists, the Australian Society for Microbiology, the Australian Institute of Medical Scientists, the Institute of Biomedical Scientists (UK) and the Australasian College of Health Service Management. In 2015 he was awarded the Order of Australia (AO) for distinguished service to tertiary education as a senior administrator and to public health as a leading immunologist, academic and researcher in the area of mucosal immunisation. Prof Cripps is a Non-Executive Director of Neurotech International Limited (ASX: NTI). He was previously Non-Executive Director of Research Australia (2005 to 2012) and the Gold Coast Hospital and Health Services Board (2011 to 2017). Prof Cripps is a member of the Company's Remuneration Committee and Audit & Risk Committee.

Mr Philip (Phil) John Powell Non-Executive Director Jun 2019

Mr Philip (Phil) John Powell

Non-Executive Director

Mr Powell is a Chartered Accountant with experience in investment banking, specialising in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other successful corporate finance assignments across a diverse range of sectors including pharma, utilities, IT, financial services, food, and agriculture. He spent 10 years in senior financial roles at OAMPS Ltd, a former ASX-listed financial services group, and 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney, and Los Angeles. Mr Powell is currently a Non-Executive Director of Medical Developments International Ltd (ASX: MVP) and RMA Global Ltd (ASX: RMY). He was a former Non- Executive Director of PolyNovo Ltd (ASX: PNV). Mr Powell is the Chair of the Company's Audit & Risk Committee

Mr Robert (Max) Maxwell Johnston Non-Executive Director Jun 2019

Mr Robert (Max) Maxwell Johnston

Non-Executive Director

Mr Johnston held the position of President and Chief Executive Officer of Johnson & Johnson Pacific, a division of the world's largest medical, pharmaceutical and consumer healthcare company for 11 years. Prior to joining Johnson & Johnson, Mr Johnston's career also included senior roles with Diageo and Unilever in Australia, Africa, and Europe. Mr Johnston has also held several prominent industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of the Australian Skills Management Institute (ASMI). Mr Johnston has had extensive overseas experience during his career in leading businesses in both Western and CentralEastern Europe and Africa as well as the Asia-Pacific region. Mr Johnston is currently Non-Executive Chairman of AusCann Group Holdings Ltd (ASX: AC8) and a Non-Executive Director of Medical Developments International Ltd (ASX: MVP). He was a former Non-Executive Director of Enero Group Limited (ASX: EGG) and PolyNovo Ltd (ASX: PNV), and a former NonExecutive Chairman of Probiotec Ltd (ASX: PBP). Mr Johnston is a member of the Company's Remuneration and Audit & Risk Committees

Dr Leearne Hinch Chief Executive Officer Nov 2016
Mrs Pauline Anne Collinson Company Secretary Nov 2001

Mrs Pauline Anne Collinson

Company Secretary

Mrs Collinson has worked for the Company for 23 years and has held the position of Company Secretary for 14 years. She is also the Company Secretary of Tanami Gold NL (ASX:TAM).

Leearne Hinch Chief Executive Officer N/A
Dr Gregory Rice Chief Scientific Officer N/A

Director Transactions

IIQ directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
13/05/22 Philip (Phil) Powell Buy +20,000 $0.531 $10,620 On-market trade
06/05/22 Geoffrey Cumming Buy +32,967 $0.609 $20,082 On-market trade
02/05/22 Philip (Phil) Powell Buy +50,000 $0.58 $29,000 On-market trade
13/12/21 Robert (Max) Johnston Issued 500,000 $1.04 $520,000 Issue of options
13/12/21 Geoffrey Cumming Issued 500,000 $1.04 $520,000 Issue of options
13/12/21 Allan Cripps Issued 500,000 $1.04 $520,000 Issue of options
13/12/21 Philip (Phil) Powell Issued 500,000 $1.04 $520,000 Issue of options
21/10/21 Philip (Phil) Powell Buy +40,000 $1.092 $43,670 On-market trade
24/08/21 Robert (Max) Johnston Buy +19,354 $1.55 $29,998 Participation in share purchase plan
24/08/21 Philip (Phil) Powell Buy +19,354 $1.55 $29,998 Participation in share purchase plan

Director Interests

The current holdings of IIQ directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Philip (Phil) Powell 13/05/2022 0 396,631 500,000 N/A
Geoffrey Cumming 06/05/2022 27,413 150,001 552,000 N/A
Robert (Max) Johnston 13/12/2021 N/A 404,310 500,000 N/A
Allan Cripps 13/12/2021 0 N/A 500,000 N/A
Pauline Collinson 10/06/2016 0 N/A N/A N/A

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Sep 6, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
The Trust Company Australia Limited <Mof A/C> 6,086,400 6.62%
Moggs Creek Pty Ltd <Moggs Creek Super A/C> 4,886,671 5.32%
HSBC Custody Nominees (Australia) Limited 4,507,239 4.90%
Dr Irmgard Irminger-Finger 4,070,000 4.43%
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 1,740,697 1.89%
J P Morgan Nominees Australia Pty Limited 1,239,572 1.35%
Traoj Pty Ltd <Traoj A/C> 1,102,933 1.20%
Mr Nathan Ryan Wagner 1,010,433 1.10%
Tony Walker 1,008,918 1.10%
Supergun Pty Ltd <Bricklanding Super Fund A/C> 1,000,000 1.09%
David Neate 902,257 0.98%
Washington H Soul Pattinson And Company Limited 745,162 0.81%
Dr Russell Kay Hancock 700,000 0.76%
Worldwise Enterprises Pty Ltd 684,354 0.74%
Citicorp Nominees Pty Limited 654,125 0.71%
UBS Nominees Pty Ltd 645,162 0.70%
Faraday Nominees Pty Limited <Bronte Investment A/C> 600,000 0.65%
B & M Laws Super Fund Pty Ltd <B & M Laws Super Fund A/C> 584,516 0.64%
Ll&P Pty Ltd <The Andrew Solomons S/F A/C> 574,095 0.62%
B & M Laws Super Fund Pty Ltd <B & M Laws Super Fund A/C> I 550,788 0.60%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 3,218 2,586 765 904 101 7,574

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Moggs Creek Pty Ltd 06/09/2021 4,886,671 5.32
Merchant Funds Management Pty Ltd 06/09/2021 11,610,762 12.63

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
24-08-21 Merchant Funds Management Pty Ltd 25,596 14.48 12.63
29-07-21 Dr Irmgard Irminger-Finger 119,520,000 5.16 4.55

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
IIQ Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.